Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Up 3.4%

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) traded up 3.4% on Tuesday . The company traded as high as $30.42 and last traded at $30.32. 97,867 shares were traded during trading, a decline of 78% from the average session volume of 448,974 shares. The stock had previously closed at $29.31.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Wednesday, March 20th. Citigroup upped their price objective on Arcturus Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 8th. Finally, William Blair reiterated an "outperform" rating on shares of Arcturus Therapeutics in a report on Friday, March 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $61.33.

Arcturus Therapeutics Price Performance

The stock has a market capitalization of $811.10 million, a price-to-earnings ratio of -28.97 and a beta of 2.60. The business has a 50 day simple moving average of $35.77 and a 200-day simple moving average of $29.73.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Thursday, March 7th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $1.37. Arcturus Therapeutics had a negative return on equity of 18.22% and a negative net margin of 15.65%. The firm had revenue of $33.99 million during the quarter, compared to analysts' expectations of $64.14 million. As a group, equities analysts predict that Arcturus Therapeutics Holdings Inc. will post -1.42 earnings per share for the current year.

Insider Buying and Selling at Arcturus Therapeutics

In other news, COO Pad Chivukula sold 17,435 shares of the company's stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $35.02, for a total transaction of $610,573.70. Following the completion of the transaction, the chief operating officer now directly owns 473,448 shares of the company's stock, valued at $16,580,148.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 13.80% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. New York State Teachers Retirement System acquired a new position in Arcturus Therapeutics during the third quarter valued at approximately $53,000. Great West Life Assurance Co. Can boosted its position in Arcturus Therapeutics by 29.9% during the first quarter. Great West Life Assurance Co. Can now owns 2,679 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 616 shares during the last quarter. AJOVista LLC acquired a new position in Arcturus Therapeutics during the fourth quarter valued at approximately $65,000. Quest Partners LLC acquired a new position in Arcturus Therapeutics during the fourth quarter valued at approximately $67,000. Finally, BNP Paribas Arbitrage SA boosted its position in Arcturus Therapeutics by 63.4% during the second quarter. BNP Paribas Arbitrage SA now owns 5,043 shares of the biotechnology company's stock valued at $79,000 after purchasing an additional 1,956 shares during the last quarter. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.